The clinical practice guidelines for heart failure recommend the use of validated risk models to estimate prognosis. Understanding how well models identify individuals who will die in the next year informs decision making for advanced treatments and hospice.
A n accurate assessment of short-term mortality is central to the care of patients with heart failure. Implantable cardioverter-defibrillators are reserved for patients "who have a reasonable expectation of meaningful survival for more than 1 year." 1(pe183) Left ventricular assist devices and transplantation are restricted to patients whose 1-year mortality without surgery exceeds the expected mortality with surgery (approximately 20% among patients with a durable left ventricular assist device). 2 Hospice eligibility relies on a physician's certification "that the patient's life expectancy is 6 months or less." 2(p32 176) Guidelines recommend using validated risk scores to estimate the risk of mortality for patients with heart failure, 1 and those "who are at high-risk for 1-year mortality using prognostic models should be referred for advanced therapy." 3(p159) The
Seattle Heart Failure Model (SHFM) is well-validated, [4] [5] [6] commonly used, and available online (https://depts.washington .edu/shfm/). 7 The Meta-Analysis Global Group in Chronic Heart Failure (MAGGIC) risk calculator is validated, increasingly used, and available online (http://www.heartfailurerisk.org). 8 Yet, the application of population-risk data to individual treatment decisions has rarely been characterized. 9,10 We compared the SHFM and MAGGIC risk calculator estimates with actual deaths at 1 year among a cohort of ambulatory patients with heart failure, for the overall population and for individual patients.
Methods
All ambulatory patients 21 years of age or older with a diagnosis of heart failure 11,12 during the period from 2005 to 2008 were identified from Kaiser Permanente Colorado, Kaiser Permanente Northwest, and Fallon Health. Baseline covariates for the risk calculators (Table 1) were extracted from electronic health records. Deaths were identified from health plan databases, state death certificates, and Social Security Administration files.
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The SHFM and MAGGIC risk calculator scores were calculated using the online algorithms. 7, 8 Mimicking the calculators, we imputed the mean values for missing data. New York Heart Association functional class, available in routine care but unavailable in electronic records, was set to functional class III in primary analysis and class IV in secondary analysis. To address concerns about model transportability, we updated the intercept and parameter estimates. The SHFM scores were converted to estimated survival at specific times using the following function: survival (t) = exp (−0.0405t)
, where t is time. The MAGGIC risk calculator estimates for mortality were mapped based on probabilities for the integer scores 0 to 50, as described in the original derivation. 8 Following the published method, 8 we used multiple imputation for the left ventricular ejection fraction, body mass index, systolic blood pressure, serum creatinine level, and smoking status. The MAGGIC risk calculator uses the left ventricular ejection fraction in interactions with age and systolic blood pressure, so we performed a secondary analysis restricted to persons with left ventricular ejection fraction data. Actual survival was described using life-table analyses to handle truncated follow-up. 14 The institutional review boards at the 3 participating sites approved the study, and waiver of consent was obtained because of the nature of the study.
Results
Among 10 930 patients with heart failure, the median age was 77 years, and 48.0% of these patients were female ( At the population level, the SHFM estimated that the 1-year mortality rate was 9.7%, with a median life expectancy of 7.0 years (interquartile range, 5.3-9.0 years; range, 3 months [shortest predicted remaining survival of anyone in the cohort] to 22 years [longest]). Discrimination was similar to other cohorts: the C statistic was 0.69 at 6 months, 0.66 at 1 year, and 0.65 at 3 years. Model calibration showed underestimations: a 6-month predicted mortality rate of 5.0% vs an observed mortality rate of 10.5%; a 1-year predicted mortality rate of 9.7% vs an observed mortality rate of 15.9%; and a 3-year predicted mortality rate of 24.6% vs an observed mortality rate of 33.6%. The Hosmer-Lemeshow test suggested an adequate model fit (χ 2 = 8.7, P = .36).
At the individual level, the SHFM performed poorly ( Figure) . The SHFM predicted a more than 50% mortality rate in the next year for 8 of the 1661 patients who actually died (sensitivity for 1-year death was 0.5%) and for 5 patients who lived at least a year (positive predictive value, 61.5%) ( Table 2) . In secondary analysis forcing the New York Heart Association to the worst functional class, the SHFM predicted a more than 50% 1-year mortality rate among 49 patients who died (sensitivity, 3.0%) and among 47 patients who lived at least a year (positive predictive value, 51.0%). Updating the SHFM intercept and parameter estimates to recalibrate and refit the model (which could not be done in clinical practice), we found that the C statistic improved (0.75) but still captured less than 8% of patients who died in the next year (of 191 patients predicted to die, 123 actually died). Conversely, the SHFM estimated that 8496 patients (77.7%) had a more than 85% probability of surviving 1 year, yet this "lower-risk" end of the score range captured nearly two-thirds of deaths (n = 997).
Key Points
Question How well do heart failure risk models perform in identifying which patients will die in the next year?
Findings In this cohort study of 10 930 adults with heart failure, 1661 patients died in the next year. One risk model predicted a more than 50% probability of dying for only 8 of those patients, and another risk model predicted death for only 52 of those patients.
Meaning Heart failure risk models perform reasonably well at the population level, but they do not reliably predict which individual patients will die in the next year. For the more stringent hospice referral threshold, the SHFM identified only 2 patients with a more than 50% probability of dying within 6 months, neither of whom died (5 patients had a New York Heart Association functional class set to IV). For a lower threshold of less than 20% 1-year mortality (which can guide a durable left ventricular assist device), the SHFM showed a sensitivity of 20.7%, a specificity of 93.1%, a positive predictive value of 39.6%, and a negative predictive value of 84.4%.
Analysis was repeated using the MAGGIC risk calculator. At the population level, the median score was 26 with a predicted 1-year mortality rate of 17.5%. The C statistic at 1 year was 0.69. The Hosmer-Lemeshow statistic had a χ 2 of 38.6 (P < .001), indicating some lack of fit in this population. In secondary analyses among the 8504 patients with available left ventricular ejection fraction data, overall risk of death was lower (1150 died [13.5%]), the C statistic was 0.70, and the Hosmer-Lemeshow χ 2 was 16.9 (P = .02).
At the individual level, the MAGGIC risk calculator also performed poorly (Figure) . It predicted a more than 50% mortality rate in the next year for 52 of the 1661 patients who actually died (sensitivity, 3.1%) and for 63 patients who lived at least a year (positive predictive value, 45.2%) ( Table 2) . Conversely, the MAGGIC risk calculator estimated that 8161 patients (74.7%) had a more than 75% probability of surviving 1 year, yet this "lower-risk" end of the score range captured the majority of deaths (n = 914). For the lower threshold of less than 20% 1-year mortality, the MAGGIC risk calculator showed a sensitivity of 69.7%, a specificity of 61.2%, a positive predictive value of 28.1%, and a negative predictive value of 90.3%.
Discussion
In this cohort of more than 10 000 ambulatory patients with heart failure, well-accepted risk models assigned a more than 50% chance of death in the next year to a very small fraction of those who actually died. Conversely, the majority of patients who died had a more than 75% model-estimated probability of surviving beyond 1 year. This highlights the limitations of applying population-based prognostic model results to short-term medical decisions about individual patients 15, 16 and may partially justify the limited uptake of risk models in routine clinical practice. 17 Most research has gone into refining risk models despite diminishing improvements in performance. Meanwhile, there is a dearth of information to help patients and health care professionals manage the uncertainty inherent in survival estimates. 18 Objective risk information should be integrated with recognition of uncertainty. 15, 19, 20 For example, prediction intervals may be more informative than median values. 21 Rather than say that "your expected survival is about 1 year," a clinician could say "if I had 100 people like you, 25 would die within 6 months and 25 would be alive after 2 years."
Limitations
Limitations should be considered. First, missing data requiring imputation may significantly relate to the poor risk pre- e A total of 1648 patients were censored owing to a lack of 1-year follow-up (25 patients with a MAGGIC-predicted survival of Յ50%).
